{"id":962161,"date":"2026-05-13T08:33:50","date_gmt":"2026-05-13T12:33:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/"},"modified":"2026-05-13T08:33:50","modified_gmt":"2026-05-13T12:33:50","slug":"gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/","title":{"rendered":"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadl1 { padding-left: 5px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwrowaltcolor0 { background-color: #cceeff }\n.bwrowaltcolor1 { background-color: #d3d3d3 }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwuline { text-decoration: underline }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }\n.bwwidth15 { width: 15% }\n.bwwidth85 { width: 85% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026<\/b><\/p>\n<p class=\"bwalignc\"><b><i>&#8211; Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers &#8211;<\/i><\/b><\/p>\n<p class=\"bwalignc\"><b><i>&#8211; Bulevirtide Data Strengthen Evidence of Efficacy and Safety Across Broad HDV Populations &#8211;<\/i><\/b><\/p>\n<p class=\"bwalignc\"><b><i>&#8211; New Findings Highlight Progress Toward HCV Elimination and Improved HDV Risk Insight &#8211;<\/i><\/b><\/p>\n<p>FOSTER CITY, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis.<\/p>\n<p>\nIn PBC, Gilead will present randomized and long-term study data for Livdelzi\u00ae (seladelpar), known as Lyvdelzi<sup>\u00ae<\/sup> in the European Union.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAnalyses from the Phase 3 RESPONSE trial (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04620733&amp;esheet=54535082&amp;newsitemid=20260512412079&amp;lan=en-US&amp;anchor=NCT04620733&amp;index=1&amp;md5=b348ba83c985ba28a14a5b5d68773d61\">NCT04620733<\/a>) will evaluate efficacy and safety in participants with risk factors for disease progress, including elevated liver stiffness and metabolic syndrome.<\/p>\n<\/li>\n<li>\nInterim data from the Phase 3 ASSURE study (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03301506&amp;esheet=54535082&amp;newsitemid=20260512412079&amp;lan=en-US&amp;anchor=NCT03301506&amp;index=2&amp;md5=3015f2af8f9dab9a82c463fa0a27ed19\">NCT03301506<\/a>) will assess the relationship between biochemical response and liver stiffness trends over 36 months, including outcomes in individuals with alkaline phosphatase (ALP) levels between 1 to 1.67x the upper limit of normal (ULN).<\/p>\n<\/li>\n<\/ul>\n<p>\nTogether these data provide a multidimensional view of Livdelzi\u2019s efficacy, safety and durability across a broad PBC population. Livdelzi is a first\u2011in\u2011class delpar (selective PPAR\u2011delta agonist) indicated for the treatment of PBC to be used in combination with ursodeoxycholic acid (UDCA) for those with an inadequate response to UDCA, or as monotherapy for patients unable to tolerate UDCA.<\/p>\n<p>\n\u201cPrimary biliary cholangitis is a chronic, progressive disease where reducing disease activity is critical to improving long\u2011term outcomes. Minimizing impact on quality of life is also key for people living with PBC,\u201d said Swati Tole, MD, MS, Senior Vice President, Clinical Development, Inflammation at Gilead Sciences. \u201cAt EASL, we are sharing data that further define Livdelzi\u2019s potential to address both disease activity and symptoms such as pruritus.\u201d<\/p>\n<p><b>Advancements in Hepatitis Delta Virus<\/b><\/p>\n<p>\nPresentations will also focus on hepatitis delta virus (HDV), a severe co\u2011infection in people with chronic hepatitis B. The program will include several analyses evaluating investigational bulevirtide, a first\u2011in\u2011class entry inhibitor, in diverse HDV patient populations, reflecting continued efforts to better understand HDV disease management and treatment approaches.<\/p>\n<p>\n\u201cPeople living with HDV face a severe disease with limited treatment options. These analyses highlight the breadth of ongoing research and Gilead\u2019s continued leadership in advancing the understanding of HDV, including efforts to evaluate Hepcludex across diverse patient populations,\u201d said Jared Baeten, MD, PhD, Senior Vice President, Clinical Development, Virology at Gilead Sciences. \u201cWe remain committed to continuously building on emerging evidence to help improve how this disease is managed over time, and we encourage clinicians to engage with evolving data to help inform care for people living with HDV.\u201d<\/p>\n<p>\nAnalyses from Phase 2 and Phase 3 studies, including MYR301 (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03852719&amp;esheet=54535082&amp;newsitemid=20260512412079&amp;lan=en-US&amp;anchor=NCT03852719&amp;index=3&amp;md5=0636c19124685d1f6c2f69b20a3aa35a\">NCT03852719<\/a>) and MYR204 (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03852433%3FviewType%3DCard%26term%3DNCT03852433%26rank%3D1&amp;esheet=54535082&amp;newsitemid=20260512412079&amp;lan=en-US&amp;anchor=NCT03852433&amp;index=4&amp;md5=846f90f5ed0bb5bc411d473a536dc007\">NCT03852433<\/a>) will evaluate clinical, virologic, and biochemical outcomes, as well as safety and tolerability, through 96 weeks across HDV subgroups.<\/p>\n<p>\nAn additional study uses a machine\u2011learning model to identify risk factors for progression to advanced liver disease in adults with HDV infection in the United States.<\/p>\n<p><b>Advancing Equitable Care for Hepatitis B and C<\/b><\/p>\n<p>\nAdditional presentations highlight progress across viral hepatitis, including HBV cure research, long\u2011term disease management, and HCV elimination efforts.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn hepatitis B, Gilead will present data from its cure research program, including studies of GS\u20112829 and GS\u20116779, evaluating HBeAg loss and immune biomarkers.<\/p>\n<\/li>\n<li>\nIn hepatitis C, presentations highlight real\u2011world elimination efforts and patient\u2011centered outcomes.<\/p>\n<\/li>\n<\/ul>\n<p><b>Key Abstracts at EASL 2026:<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>ID<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Abstract Title<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b><i>PBC<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Clinical Data<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nLBP-037<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSeladelpar leads to decreases in serum proteins associated with PBC disease severity: proteomic analysis from the pivotal RESPONSE trial<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSAT-316<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEfficacy and safety of seladelpar in patients with primary biliary cholangitis and alkaline phosphatase levels between 1 and 1.67 \u00d7 upper limit of normal: interim results from the open-label ASSURE study<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTHU-270<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nBiochemical response is associated with liver stiffness stability in patients with primary biliary cholangitis treated with seladelpar for up to 36 months: interim results from the open-label ASSURE study<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSAT-363<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEfficacy and safety of seladelpar in patients with primary biliary cholangitis and risk factors for progression including younger age at diagnosis or higher liver stiffness in the pivotal RESPONSE study<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSAT-362<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEfficacy and safety of seladelpar vs placebo in patients with primary biliary cholangitis and metabolic syndrome in the pivotal phase 3 RESPONSE study<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>RWE<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSAT-306<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nDemographic and clinical characteristics of United States real-world patients with primary biliary cholangitis and alkaline phosphatase between 1 and 1.67 vs &gt;1.67 \u00d7 upper limit of normal despite ursodeoxycholic acid treatment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>HEOR<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSAT-387<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nMeaningful within-patient change on the 5-D itch scale in patients with primary biliary cholangitis experiencing pruritus<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b><i>HDV<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Clinical Data<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFRI-587<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nBulevirtide monotherapy is safe and well tolerated in chronic hepatitis delta: An integrated safety analysis of bulevirtide clinical trials at week 96<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nWED-593<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nIntegrated efficacy analysis of bulevirtide 10 mg from studies MYR204 and MYR301 at weeks 48 and 96 across subgroups<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nWED-576<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSafety of bulevirtide 10 mg is consistent across demographic and clinical subgroups: Results from an integrated analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>RWE<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFRI-031<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPredictors of advanced liver disease events among individuals with hepatitis delta virus infection in a large United States administrative claims dataset: a machine learning analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>HEOR<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFRI-605<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nImpact of bulevirtide treatment on patient-reported outcomes among patients with hepatitis delta in Europe<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b><i>HCV<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>RWE<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nWED-047<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nProgress towards hepatitis C virus elimination in English prisons &#8211; 7-year outcomes on a multi-stakeholder project<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b><i>HBV<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Clinical Data<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFRI-624<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFactors associated with lack of alanine aminotransferase normalization in patients with chronic hepatitis B virus after 8 years of tenofovir-based treatment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>RWE<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFRI-030<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSynergistic effect of diabetes and hypertension on the risk of liver disease progression in hepatitis B virus infection<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><b><i>HBV Cure<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Clinical Data<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nWED-580<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nBaseline and on-treatment characteristics of HBeAg-positive patients and correlates of HBeAg loss following GS-2829 and GS-6779 therapeutic vaccination in virally suppressed patients with chronic hepatitis B<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth15\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nWED-578<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth85\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nTranscriptomic profiling reveals distinct immune signatures in chronic hepatitis B and identifies blood transcriptional modules associated with hepatitis B e antigen loss<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nFor more information, including a complete list of abstract titles being presented at the meeting, please visit the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.easlcongress.eu%2Fwp-content%2Fuploads%2F2026%2F03%2FList-of-accepted-regular-abstracts.pdf&amp;esheet=54535082&amp;newsitemid=20260512412079&amp;lan=en-US&amp;anchor=EASL+website&amp;index=5&amp;md5=83e926feb828be88c2c28cc145b13d28\">EASL website<\/a>.<\/p>\n<p>\nPlease see below for the U.S. Indications and Important Safety Information for Livdelzi.<\/p>\n<p><b><span class=\"bwuline\">Marketing Authorizations for Bulevirtide<\/span><\/b><\/p>\n<p>\nIn July 2023, the European Commission granted full Marketing Authorization (MA) for Hepcludex (bulevirtide) 2 mg for the treatment of adults with chronic hepatitis delta virus (HDV) infection and compensated liver disease (conditional approval was received in July 2020). Hepcludex 2 mg also has full marketing authorization in the United Kingdom, Switzerland, Australia, Canada, United Arab Emirates, Israel and Kuwait.<\/p>\n<p>\nBulevirtide is not approved in the United States. In the U.S. and other regions where it is not authorized, bulevirtide 2 mg is an investigational product, and its safety and efficacy have not been established or approved by the U.S. Food and Drug Administration (FDA) or other health authorities.<\/p>\n<p>\nBulevirtide 10 mg, GS-2328 and GS-6779 are investigational and not approved anywhere globally. The safety and efficacy of these programs have not been established.<\/p>\n<p><b><span class=\"bwuline\">U.S. Indication for Livdelzi<\/span><\/b><\/p>\n<p>\nLivdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. The FDA approved this indication under accelerated approval based on a reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).<\/p>\n<p><b><span class=\"bwuline\">Limitations of Use for Livdelzi:<\/span><\/b><\/p>\n<p>\nUse of Livdelzi is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).<\/p>\n<p><b><span class=\"bwuline\">U.S. Important Safety Information for LIVDELZI<\/span><\/b><\/p>\n<p><b><span class=\"bwuline\">Warnings and Precautions<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFractures: Fractures occurred in 4% of LIVDELZI-treated patients compared to no placebo-treated patients. Consider the risk of fracture in the care of patients treated with LIVDELZI and monitor bone health according to current standards of care.<\/p>\n<\/li>\n<li>\nLiver Test Abnormalities: LIVDELZI has been associated with dose-related increases in serum transaminase (AST and ALT) levels &gt; 3 x ULN in patients receiving 50 mg and 200 mg once daily (5x and 20x higher than the recommended dosage of 10 mg once daily). Perform baseline clinical and laboratory testing when starting LIVDELZI and monitor thereafter according to routine patient management. Interrupt treatment if the liver tests (ALT, AST, total bilirubin, and\/or ALP) worsen, or if the patient develops signs and symptoms of clinical hepatitis (eg, jaundice, right upper quadrant pain, eosinophilia). Consider permanent discontinuation if liver tests worsen after restarting LIVDELZI.<\/p>\n<\/li>\n<li>\nBiliary Obstruction: Avoid use of LIVDELZI in patients with complete biliary obstruction. If biliary obstruction is suspected, interrupt LIVDELZI and treat as clinically indicated.<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Adverse Reactions<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe most common adverse reactions (\u22655%) with LIVDELZI were headache (8%), abdominal pain (7%), nausea (6%), abdominal distension (6%), and dizziness (5%).<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Drug Interactions<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nOAT3 Inhibitors and Strong CYP2C9 Inhibitors: Avoid coadministration with LIVDELZI due to increased LIVDELZI exposure.<\/p>\n<\/li>\n<li>\nRifampin: Monitor biochemical response (e.g., ALP and bilirubin) when patients initiate rifampin during LIVDELZI treatment. Coadministration may result in delayed or suboptimal biochemical response of LIVDELZI.<\/p>\n<\/li>\n<li>\nDual Moderate CYP2C9 and Moderate-to-Strong CYP3A4 Inhibitors and BCRP Inhibitors (eg, cyclosporine): Monitor closely for adverse effects. Concomitant administration with LIVDELZI may increase LIVDELZI exposure.<\/p>\n<\/li>\n<li>\nCYP2C9 Poor Metabolizers Using Moderate-to-Strong CYP3A4 Inhibitors: Monitor more frequently for adverse reactions as concomitant use of a moderate-to-strong CYP3A4 inhibitor in patients who are CYP2C9 poor metabolizers may increase LIVDELZI exposure and risk of LIVDELZI adverse reactions.<\/p>\n<\/li>\n<li>\nBile Acid Sequestrants: Administer LIVDELZI at least 4 hours before or 4 hours after taking a bile acid sequestrant, or at as great an interval as possible.<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Pregnancy and Lactation<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPregnancy: There are insufficient data from human pregnancies exposed to LIVDELZI to allow an assessment of a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Report pregnancies to Gilead Sciences, Inc., at 1-800-445-3235.<\/p>\n<\/li>\n<li>\nLactation: There are no data on the presence of LIVDELZI in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother&#8217;s clinical need for LIVDELZI and any potential adverse effects on the breastfed infant from LIVDELZI.<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">About Gilead Sciences in Liver Disease<\/span><\/b><\/p>\n<p>\nFor decades, Gilead has pioneered the way forward to improve the lives of people living with liver disease around the world. We have helped to transform hepatitis C from a chronic condition into one that can be cured for millions of people. For people living with hepatitis B or D, our focus on advancing our medicines drives hope that today\u2019s research will turn into tomorrow\u2019s cures. Beyond viral hepatitis, we\u2019re working to deliver advanced treatments for people living with PBC. But our commitment doesn\u2019t stop there. Through our ground-breaking science and collaborative partnerships, we strive to create healthier futures for everyone living with liver disease. We are committed to a future without liver disease.<\/p>\n<p><b><span class=\"bwuline\">About Gilead Sciences<\/span><\/b><\/p>\n<p>\nGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.<\/p>\n<p><b><span class=\"bwuline\">Forward-Looking Statements<\/span><\/b><\/p>\n<p>\nThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead\u2019s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials or studies, including those involving bulevirtide, Livdelzi, GS-2829 and GS-6779 (such as RESPONSE, ASSURE, MYR301 and MYR204); uncertainties relating to regulatory applications and related filing and approval timelines, including additional pending and potential applications for programs and\/or indications currently under evaluation, and the risk that any such approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead\u2019s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.<\/p>\n<p class=\"bwalignc\"><i>Hepcludex, Livdelzi, Lyvdelzi, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.<\/i><\/p>\n<p class=\"bwalignc\"><i>U.S. full Prescribing Information for Livdelzi is available at <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com&amp;esheet=54535082&amp;newsitemid=20260512412079&amp;lan=en-US&amp;anchor=www.gilead.com&amp;index=6&amp;md5=6065d5f21b3b848ec9854f4c81548b43\"><i>www.gilead.com<\/i><\/a><i>.<\/i><\/p>\n<p class=\"bwalignc\"><i>For more information about Gilead, please visit the company\u2019s website at <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com&amp;esheet=54535082&amp;newsitemid=20260512412079&amp;lan=en-US&amp;anchor=www.gilead.com&amp;index=7&amp;md5=bf270d1b9e77f6370a80d9de7e0cdeac\"><i>www.gilead.com<\/i><\/a><i>, follow Gilead on X\/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260512412079\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260512412079\/en\/<\/a><\/span><\/p>\n<p>\nPriscilla White, Media<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:public_affairs@gilead.com\">public_affairs@gilead.com<\/a><\/p>\n<p>\nJacquie Ross, Investors<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor_relations@gilead.com\">investor_relations@gilead.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California Europe Spain United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Health Infectious Diseases Hospitals Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260512412079\/en\/778437\/3\/GCP_Primarylarge_1.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 &#8211; Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers &#8211; &#8211; Bulevirtide Data Strengthen Evidence of Efficacy and Safety Across Broad HDV Populations &#8211; &#8211; New Findings Highlight Progress Toward HCV Elimination and Improved HDV Risk Insight &#8211; FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962161","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 &#8211; Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers &#8211; &#8211; Bulevirtide Data Strengthen Evidence of Efficacy and Safety Across Broad HDV Populations &#8211; &#8211; New Findings Highlight Progress Toward HCV Elimination and Improved HDV Risk Insight &#8211; FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study &hellip; Continue reading &quot;Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T12:33:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026\",\"datePublished\":\"2026-05-13T12:33:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/\"},\"wordCount\":2324,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/\",\"name\":\"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-05-13T12:33:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/","og_locale":"en_US","og_type":"article","og_title":"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 - Market Newsdesk","og_description":"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 &#8211; Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers &#8211; &#8211; Bulevirtide Data Strengthen Evidence of Efficacy and Safety Across Broad HDV Populations &#8211; &#8211; New Findings Highlight Progress Toward HCV Elimination and Improved HDV Risk Insight &#8211; FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study &hellip; Continue reading \"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-13T12:33:50+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026","datePublished":"2026-05-13T12:33:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/"},"wordCount":2324,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/","name":"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-05-13T12:33:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260512412079r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-to-present-new-data-advancing-care-in-pbc-and-viral-hepatitis-at-easl-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962161"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962161\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}